

10/583950

AP3 Rec'd PCT/PTO 20 JUN 2006

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			
INFORMATION DISCLOSURE STATEMENT		Docket Number: 11847/46101	
Application Number: Not Yet Assigned	Filing Date: Herewith	Examiner: Not Yet Assigned	Art Unit: Not Yet Assigned
Title: VACCINE		Applicant(s): Rolf KIESSLING et al.	

Address to:

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 37 C.F.R. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorney(s) for Applicant(s) hereby bring the reference(s) listed on the attached modified PTO Form No. 1449 to the attention of the Examiner. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

2. A copy of each patent, publication or other information listed on the modified PTO form 1449 is enclosed, except as otherwise indicated.

Respectfully submitted,

Dated:

By: Carmella L. Stephens
Carmella L. Stephens (Reg. No. 41,328)

KENYON & KENYON LLP
One Broadway
New York, N.Y. 10004
(212) 425-7200 (telephone)
(212) 425-5288 (facsimile)
CUSTOMER NO. 26646

40/583950
AP3 Rec'd PCT/PTO 20 JUN 2003

INFORMATION DISCLOSURE STATEMENT BY APPLICANT PTO-1449	LOCKED 11847/46101	Not Yet Assigned
	APPLICANT Rolf KIESSLING et al.	
	FILING DATE Herewith	GROUP Not Yet Assigned

U. S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT/PUBLICATION NUMBER	PATENT/PUBLICATION DATE	NAME	CLASS	SUBCLASS	FILING DATE*

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						Yes	No
	WO 03/037931	May 8, 2003	PCT				
	WO 99/66038	December 23, 1999	PCT				

OTHER DOCUMENTS

EXAMINER INITIAL		AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
		Troyanovsky B et al., Angiomotin: An angiostatin binding protein that regulates endothelial cell migration and tube formation, March 19, 2001, The Journal of Cell Biology, Rockefeller University Press, US. Vol. 152, no. 6, pages 1247-1254
		Bratt A Et al., Angiomotin belongs to a novel protein family with conserved coiled-coil and PDZ binding domains, September 18, 2002, Gene: An International Journal on Genes and Genomes, Elsevier Science Publishers, Vol. 298, no. 1, pages 69-77
		Levchenko Tetyana et al, Loss of responsiveness to chemotactic factors by deletion of the C-terminal protein interaction site of Angiomotin, Journal of Cell Science, Vol. 116, no. 18, pages 3803-3810
		Jiang W G et al, Angiomotin and Angiomotin like proteins, their expression and correlation with angiogenesis in human breast cancer, December 03-06, 2003, Brest Cancer Research and Treatment, Vol. 82, no. Supplement 1, 2003, pages S134-S135
		Li Yiwen et al., Vaccination against angiogenesis-associated antigens: A novel cancer immunotherapy strategy, December 2003, Current Molecular Medicine (Hilversum), Vol. 3, no. 8, pages 773-779
		Scappaticci Frank A, The therapeutic potential of novel antiangiogenic therapies, June 2003, Expert Opinion on Investigational Drugs, Vol. 12, no. 6, pages 923-932
		Brossart Peter et al., Dendritic cells in cancer vaccines, November 2001, Experimental Hematology (Charlottesville) Vol. 29, no. 11, pages 1247-1255

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

EV 839709720 US